Harrow, Inc. (NASDAQ:HROW - Get Free Report)'s stock price crossed above its 50 day moving average during trading on Wednesday. The stock has a 50 day moving average of $30.31 and traded as high as $32.52. Harrow shares last traded at $32.16, with a volume of 865,224 shares traded.
Analysts Set New Price Targets
Several equities research analysts have issued reports on HROW shares. BTIG Research reiterated a "buy" rating and issued a $63.00 price target on shares of Harrow in a research note on Wednesday, November 11th. Leerink Partners started coverage on Harrow in a research report on Wednesday, September 9th. They set an "outperform" rating and a $45.00 price target on the stock. Wall Street Zen raised shares of Harrow from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Zacks Research downgraded shares of Harrow from a "hold" rating to a "strong sell" rating in a research report on Tuesday, November 3rd. Finally, Weiss Ratings upgraded Harrow from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, November 13th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $66.20.
Read Our Latest Research Report on HROW
Harrow Stock Performance
The company has a debt-to-equity ratio of 10.15, a current ratio of 2.29 and a quick ratio of 2.12. The company has a fifty day moving average price of $30.31 and a two-hundred day moving average price of $37.35. The company has a market capitalization of $1.21 billion, a P/E ratio of -41.23 and a beta of 0.18.
Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.06. The firm had revenue of $99.30 million during the quarter, compared to analyst estimates of $98.59 million. Harrow had a negative net margin of 9.39% and a negative return on equity of 69.81%. Equities analysts forecast that Harrow, Inc. will post -0.50 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Harrow
A number of hedge funds have recently added to or reduced their stakes in HROW. KBC Group NV purchased a new position in Harrow in the first quarter worth $31,000. Sterling Capital Management LLC increased its holdings in Harrow by 836.8% in the 3rd quarter. Sterling Capital Management LLC now owns 1,068 shares of the company's stock worth $33,000 after acquiring an additional 954 shares during the last quarter. Toronto Dominion Bank purchased a new stake in Harrow during the third quarter valued at about $46,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Harrow during the third quarter worth about $59,000. Finally, First Bancorp Inc ME bought a new position in Harrow during the second quarter worth about $64,000. Institutional investors and hedge funds own 72.76% of the company's stock.
About Harrow
(
Get Free Report)
Harrow is a pharmaceutical company focused on developing, acquiring and commercializing treatments for eye conditions. Its portfolio includes prescription ophthalmic medicines used in areas such as dry eye disease, eye inflammation and pain management, as well as products used in eye surgery and clinical settings. The company markets branded products including VEVYE, a treatment for dry eye disease, and IHEEZO, an ophthalmic anesthetic gel. Through its ImprimisRx subsidiary, Harrow also provides compounded medications and related services for ophthalmology practices and patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Harrow, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.
While Harrow currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.